Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1038/d41586-022-02803-8 | DOI Listing |
Helicobacter
January 2025
Department of Public Health, University of Otago, Wellington, South, New Zealand.
Background: As seen globally, there are up to sixfold differences in gastric cancer mortality by ethnicity in Aotearoa New Zealand, and H. pylori is the major modifiable risk factor. This study investigates whether current H.
View Article and Find Full Text PDFMini Rev Med Chem
January 2025
University of Bucharest, Faculty of Biology, DAFAB Department, Splaiul Independentei 91-95, Bucharest, R-050095, Romania.
The use of biomaterials in treating and managing chronic wounds represents a significant challenge in global healthcare due to the complex nature of these wounds, which are slow to heal and can lead to complications such as frequent infections and diminished quality of life for patients. Chronic wounds, which can arise from conditions like diabetes, poor circulation, and pressure sores, pose distinct challenges in wound care, necessitating the development of specialized dressings. The pathophysiology of chronic wounds is thoroughly examined in this article, with particular attention paid to the cellular and molecular defects at work and the therapeutic guidelines.
View Article and Find Full Text PDFJ Biomed Opt
June 2024
Food and Drug Administration, Center for Devices and Radiological Health, Silver Spring, Maryland, United States.
Significance: Pulse oximeter measurements are commonly relied upon for managing patient care and thus often require human testing before they can be legally marketed. Recent clinical studies have also identified disparities in their measurement of blood oxygen saturation by race or skin pigmentation.
Aim: The development of a reliable bench-top performance test method based on tissue-simulating phantoms has the potential to facilitate pre-market assessment and the development of more accurate and equitable devices.
Neurooncol Pract
February 2025
Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
The isocitrate dehydrogenase (IDH) inhibitor, vorasidenib, may offer a promising new treatment option for patients with IDH-mutant gliomas. However, the indefinite nature of this targeted therapy raises significant financial concerns. High costs of targeted cancer therapies, often exceeding $150 000 annually, contribute to financial toxicity, characterized by medical debt, income loss, and psychological stress, and place stress on health systems.
View Article and Find Full Text PDFFront Public Health
January 2025
Promoting Positive Change, LLC, Annapolis, MD, United States.
Children living in households where parents or caregiving adults misuse substances face significant risk academically, socially, physically, and emotionally. An estimated 12% or more of U.S.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!